Core Insights - Shanghai Meino Biological Technology Co., Ltd. reported a revenue of 236 million yuan for the first half of 2025, representing a year-on-year growth of 13.69% [1] - The company's net profit attributable to shareholders reached 23.53 million yuan, up 17.68% year-on-year, while the net profit after deducting non-recurring items was 21.84 million yuan, reflecting a growth of 27.46% [1] Market Strategy - The company adheres to a market strategy of "deepening domestic operations and breaking into international markets" and a product strategy of "diversified seeds and products, full-process nutrition" [1] - Meino Biological aims to become a global leader in animal nutrition technology, emphasizing its mission of providing better solutions for animals and humans [1] International Business Performance - The company's international business continues to perform well, with a dual approach of "going out" to develop new markets and "digging in" to deepen existing market value [1] - The revenue from international business has approached 40% of the company's total operating income, maintaining a growth rate of over 20% [1] Product Development - The company focuses on industry demands for "quality improvement and efficiency enhancement" and "green safety," continuously developing efficient, safe, and environmentally friendly feed additives and hydrolyzed protein feed raw materials [2] - The revenue from the main feed additive and hydrolyzed protein feed raw material business has seen varying degrees of growth compared to the same period last year, with the intestinal health product segment experiencing over 60% year-on-year growth, significantly contributing to the company's overall performance [2]
美农生物上半年营收净利均实现双位数增长 肠道健康类产品收入同比增长超60%